SMCHD1 pathways as candidate targets for FSHD

SMCHD1 通路作为 FSHD 的候选靶点

基本信息

批准号：
8687333
负责人：
Stephen J Tapscott
金额：
$ 48.07万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-25 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8687333
关键词：
Amino Acid Sequence Biological Process Cell Culture Techniques Cell Differentiation process Cells Chromatin Complex D4Z4 Data Defect Epigenetic Process Facioscapulohumeral Facioscapulohumeral Muscular Dystrophy Failure Fibroblasts Future Genes Genetic Epistasis Genetic Transcription Goals Half-Life Haplotypes Health Immunoprecipitation Individual Investigation Ligase Lysine Mass Spectrum Analysis Mediating Messenger RNA Modification Molecular Muscle Cells Muscle Fibers Muscular Dystrophies Mutation Myoblasts Orthologous Gene Pathway interactions Peptide Hydrolases Peptide Sequence Determination Physiologic pulse Post-Translational Regulation Predisposition Production Protein Isoforms Proteins RNA Sequences Regulation Repression Research Research Design Role Skeletal Muscle Splice-Site Mutation Testing Therapeutic Translations Variant base chromosome 18p deletion syndrome cohesin condensin knock-down public health relevance research study therapeutic development therapy development

项目摘要

DESCRIPTION (provided by applicant): Facioscapulohumeral dystrophy (FSHD) is caused by decreased epigenetic repression of the D4Z4 repeat that results in expression of the DUX4 retrogene. Mutations in SMCHD1 result in decreased D4Z4 epigenetic repression through its direct repressor activity at the D4Z4 repeat and cause FSHD. The broad and long-term goal of this application is to develop therapies for FSHD based on increasing SMCHD1 activity or protein level, or decreasing the activity of factor(s) that counter-act SMCHD1 epigenetic activity at the D4Z4 repeats. The specific goal of the research design is to determine the positive and negative modulators of SMCHD1 activity and their epistatic relationship to the epigenetic repression of the D4Z4 macrosatellite repeat and DUX4 expression. Aim 1 will identify the molecular components and the biological functions of the pathways that regulate the post-transcriptional and post-translational production and activity of SMCHD1, and provide a rational basis for the therapeutic modulation of SMCHD1 in FSHD muscle. Aim 2 will test the hypothesis that FSHD2-associated SMCHD1 variants partially inhibit the activity or stability of the wild-type protein and provide a rationale to target the variant isoforms as a therapeutic approach. Aim 3 Identifies components of the SMCHD1 repressive complex and determines their role in D4Z4 epigenetic repression. Together, these studies will provide the basis for future therapeutic development based on increasing the epigenetic repression of D4Z4 in FSHD individuals.

描述（由申请人提供）：Facioscapulohumeral营养不良（FSHD）是由D4Z4重复的表观遗传抑制降低引起的，从而导致DUX4逆转表表达。 SMCHD1的突变导致D4Z4表观遗传抑制降低，其直接抑制剂在D4Z4重复时的直接抑制作用并引起FSHD。该应用的广泛和长期目标是基于增加SMCHD1活性或蛋白质水平的FSHD疗法，或者降低了对D4Z4重复序列中的SMCHD1表观遗传活性的因子的活性。研究设计的具体目标是确定SMCHD1活性的正和阴性调节剂及其与D4Z4宏观片剂重复和DUX4表达的表观遗传抑制的同志关系。 AIM 1将确定调节SMCHD1转录后和翻译后产生和活性的途径的分子成分以及生物学功能，并为FSHD肌肉中SMCHD1的治疗调制提供了合理的基础。 AIM 2将检验以下假设：FSHD2相关的SMCHD1变体部分抑制了野生型蛋白的活性或稳定性，并提供了将变体同工型作为治疗方法靶向的理由。 AIM 3标识了SMCHD1抑制复合物的组成部分，并确定它们在D4Z4表观遗传抑制中的作用。总之，这些研究将为未来的治疗发展提供基础，以增加FSHD个体中D4Z4的表观遗传抑制作用。